×
About 5,334 results
FDA approves first generics of Gilenya
https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-gilenya
FDA

Dec 8th, 2019 - The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.

BIOGEN AND ALKERMES ANNOUNCE FDA APPROVAL OF VUMERITY™ (DIROXIMEL FUMARATE) FOR MULTIPLE SCLEROSIS
http://investors.biogen.com/news-releases/news-release-details/biogen-and-alkermes-announce-fda-approval-vumeritytm-diroximel

Nov 5th, 2019 - Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease...

Cannabis and cannabinoids for people with multiple sclerosis
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013444/full

Oct 6th, 2019 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess benefit and safety of cannabis‐based medicines, including synthetic, or herbal and plant‐derived cannabinoids, for people with MS.

FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
http://media.emdserono.com/2019-03-29-FDA-Approves-MAVENCLAD-R-Cladribine-Tablets-as-First-and-Only-Short-Course-Oral-Treatment-for-Relapsing-Remitting-and-Active-Secondary-Progressive-Multiple-Sclerosis

Mar 28th, 2019 - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). MAVENCLAD is the first and only FDA-approved treatment for RRMS and ...

Landmark Study Estimates Nearly 1 Million in the U.S. Have Multiple Sclerosis
https://www.nationalmssociety.org/About-the-Society/News/Landmark-Study-Estimates-Nearly%C2%A01-Million-in-the-U

Feb 14th, 2019 - A study by leading experts estimates that in 2017, nearly 1 million adults (up to 913,925) were living with MS in the United States. This is more than twice the previously reported number from a national study in 1975 and subsequent updates.

Baclofen
https://www.ncbi.nlm.nih.gov/books/NBK526037/

Dec 15th, 2018 - Baclofen was originally designed in 1960 to treat epilepsy. However, the result was not satisfactory. Baclofen was then reintroduced in 1971 when it was found to treat muscle spasticity and has been widely used since. Baclofen is FDA-approved for the management of reversible spasticity, particularly for the relief of flexor spasms, clonus, and concomitant pain, common sequelae of spinal cord le...

Medical Use of Cannabinoids
https://link.springer.com/article/10.1007/s40265-018-0996-1
Drugs Fraguas-Sánchez, A. et. al.

Oct 28th, 2018 - Cannabinoid receptors, endocannabinoids and the enzymes responsible for their biosynthesis and degradation constitute the endocannabinoid system. In recent decades, the endocannabinoid system has attracted considerable interest as a potential therapeutic target in numerous pathological conditions. Its involvement in several physiological processes is well known, such as in energy balance, appet...

Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329850/
BioMed Research International;

Jan 30th, 2015 - Multiple sclerosis (MS) is a chronic central nervous system disease with a highly heterogeneous course. The aetiology of MS is not well understood but is likely a combination of both genetic and environmental factors. Approximately 85% of patients present with relapsing-remitting MS (RRMS), while 10–15% present with primary progressive MS (PPMS). PPMS is associated with an older onset age, a di...

Neurodiem, your daily connection to neuroscience
https://www.neurodiem.com/

Independent, unbiased, and scientifically validated content covering 18 topics including headache, cognition, dementia, pain, epilepsy, movement disorders, neurosurgery, neuro-oncology, multiple sclerosis etc.

What Causes MS? : National Multiple Sclerosis Society
https://www.nationalmssociety.org/What-is-MS/What-Causes-MS

While the cause (etiology) of MS is still not known, scientists believe that the interaction of several different factors may be involved.

MAVENCLAD® (cladribine) tablets: Now Approved | HCP
https://www.mavenclad.com/en/now-approved/hcp

Find HCP information about MAVENCLAD® (cladribine) tablets, an oral therapy. See Full Prescribing & Safety Info, including BOXED WARNING. MAVENCLAD is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS)

NOVANTRONE® mitoXANTRONE for injection concentrate
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf

NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses)

AVONEX® (interferon beta-1a)
https://www.avonex.com/en_us/home/additional-support/hcp-resources.html

Find resources about AVONEX (interferon beta-1a) for healthcare professionals, including start forms, insurance information, and formulary access. AVONEX is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS)

BETASERON® (interferon beta-1b)
https://www.betaseron.com/hcps/

BETASERON® information for healthcare professionals. BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations.

Impact of polypharmacy in RRMS
https://www.mdedge.com/neurology/msresourcecenter/article/211425/multiple-sclerosis/impact-polypharmacy-rrms?channel=251

Nov 1st, 2019 - Key clinical point: Polypharmacy frequency can have a negative effect on relapsing-remitting multiple sclerosis (RRMS) patients. Major finding: The proportion of polypharmacy among patients with a secondary illness to RRMS was four times higher than in patients without a secondary illness.

Algorithms help identify RRMS patients
https://www.mdedge.com/neurology/msresourcecenter/article/211424/multiple-sclerosis/algorithms-help-identify-rrms-patients?channel=251

Nov 1st, 2019 - Key clinical point: Two algorithms identified in a new study can be used for future clinical research of relapsing-remitting multiple sclerosis (RRMS). Major finding: Using EHRs and the coded health care claims of 5,308 patients with possible MS, 837 and 2,271 were identified as having RRMS, respectively.

Small Relief for Biogen in MS Drug Approval
https://www.medscape.com/viewarticle/920587

Oct 31st, 2019 - (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Biogen Inc's new oral drug to treat multiple sclerosis, offering the drugmaker some relief as its core franchise faces patent challenges. Shares of Cambridge, Massachusetts-based Biogen rose 2.6% to $305.25 in early trade. Biogen said it would make the new drug, Vumerity, available in the United States in the near future bu...

PRAC Updates Restrictions on Alemtuzumab for MS
https://www.medscape.com/viewarticle/920640

Oct 30th, 2019 - The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has updated restrictions on the use of alemtuzumab (Lemtrada, Genzyme) for patients with relapsing-remitting multiple sclerosis (MS) to help minimize the risk for serious side effects. At its October meeting, the committee advised that alemtuzumab only be used in adults who have highly active disease d...

FDA approves diroximel fumarate for relapsing MS
https://www.mdedge.com/neurology/msresourcecenter/article/211248/multiple-sclerosis/fda-approves-diroximel-fumarate?channel=251
Jake Remaly

Oct 30th, 2019 - The Food and Drug Administration has approved diroximel fumarate (Vumerity) for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, according to an Oct. 30 announcement from its developers, Biogen and Alkermes.

Adolescent Lung Inflammation May Trigger Later MS
https://www.mdedge.com/neurology/msresourcecenter/article/211234/multiple-sclerosis/adolescent-lung-inflammation-may?channel=251

Oct 30th, 2019 - Key clinical point: Inflammatory pulmonary events occurring at age 11-15 years may be a risk factor for subsequent multiple sclerosis. Major finding: Swedes who experienced pneumonia at age 11-15 years had an adjusted 2.